Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | ERN1 | O75460 | 4/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MPI | P34949 | 1/20 | 0.30 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2599740 | 0.83 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2PTPN1ERN1KDM4E | |
| SCHEMBL671605 | 0.79 | PDE4B (0.46) | ALDH1A1SMN1; SMN2CYP2A6PTPN1ERN1 | |
| SCHEMBL2599851 | 0.78 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL670294 | 0.76 | CYP2A6 (0.41) | ALDH1A1SMN1; SMN2CYP2A6PTPN1ERN1 | |
| SCHEMBL2599821 | 0.75 | TRIM24 (0.42) | ALDH1A1SMN1; SMN2CYP2A6KDM4EMEN1 | |
| SCHEMBL2599810 | 0.71 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2CYP2A6KDM4EMEN1 | |
| SCHEMBL2599736 | 0.71 | ERN1 (0.40) | ALDH1A1SMN1; SMN2PTPN1ERN1KDM4E | |
| SCHEMBL23497546 | 0.70 | PTPN1 (0.41) | ALDH1A1SMN1; SMN2CYP2A6PTPN1ERN1 | |
| SCHEMBL29744434 | 0.70 | PTPN1 (0.41) | ALDH1A1SMN1; SMN2CYP2A6PTPN1ERN1 | |
| SCHEMBL22938833 | 0.69 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2ERN1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2605658-B1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME (US) | 2016-03-23 | — | — | EP | disclosed |
| US-8742110-B2 | Spiroxazolidinone compounds | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2605658-A1 | SPIROXAZOLIDINONE COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2571356-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20130040978-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | MERCK SHARP & DOHME CORP | 2013-02-14 | — | — | US | disclosed |
| WO-2012024183-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2011146324-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | SSTR5, SSTR2, SSTR4 | ALDH1A1 1467/4885SMN1; SMN2 3345/4885CYP2A6 1930/4885 |
| US-20130040978-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | SSTR5, SSTR2, SSTR1 | ALDH1A1 1103/4885SMN1; SMN2 2690/4885CYP2A6 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.